Navigating these demands can be challenging, particularly within the constraints of local health systems and the expectations of healthcare professionals and their patients.
In this webinar, the attendees will get to learn about practical solutions and advanced technologies to enhance their ability to efficiently monitor and respond to risks, ensure regulatory compliance, improve decision-making and ultimately safeguard public health. They will also gain insights into:
How to adapt and apply RMPs effectively across diverse healthcare systems while addressing the needs of healthcare professionals and patients
How to leverage digital tools and platforms to enhance RMP monitoring and implementation
The key methods to measure and monitor RMP/RMM effectiveness
How pharmacovigilance leadership, EU Qualified Person Responsible for Pharmacovigilance (QPPV) and Local Person for Pharmacovigilance (LPPV) can maintain appropriate oversight
Register for this webinar today for insights and knowledge that can help effectively navigate the digital transformation in pharmacovigilance.
Join experts from ICON, Steve Bowers, Director, Pharmacovigilance & Safety Services; and Rakan Bitar, Senior Director, Pharmacovigilance & Safety Services, for the live webinar on Thursday, September 12, 2024, at 11am EDT (4pm BST/UK).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
This webinar offers insights on ensuring data and results are kept safe and secure, addressing best practices for data protection and security measures in statistical computing. This information will equip attendees with the knowledge to enhance the integrity and reliability of their statistical analyses and maintain compliance with regulatory standards.
In this webinar, the expert speakers will also delve into the essential elements required to establish a robust statistical computing environment. Attendees will learn about the core needs of such an environment, including what must be monitored to maintain audit readiness. The discussion will also cover the components of a complete validation document set, providing a comprehensive guide on effectively preparing and organizing these critical documents.
Join experts from Instem, Joe Olinger, Solution Owner, Phil Loucks, Account Manager, and special guest Karena Kong, Senior Director of Statistical Programming for the live webinar on Wednesday, September 11, 2024, at 2pm EDT (11am PDT).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
“Salesian missionaries are on the forefront of humanitarian efforts in more than 130 countries around the globe and aid in humanitarian relief during times of natural disasters, traumatic circumstances and civil strife,” explained Father Michael Conway, director of Salesian Missions. “Because Salesian missionaries live in the communities they serve, they are often on the front lines of humanitarian disasters. Whether providing clothing and shelter in the immediate aftermath or assisting the long recovery process to help families rebuild their homes and salvage their livelihoods, Salesians are perfectly positioned to help.”
In honor and celebration of World Humanitarian Day 2024, Salesian Missions is proud to highlight humanitarian and transformative programming in countries around the globe.
DR CONGO People who have been internally displaced and are living at Camp Don Bosco, located at the Don Bosco Ngangi Youth Center in Goma, Democratic Republic of the Congo*, had access to healthy nutrition thanks to a partnership between Salesian Missions and Feed My Starving Children. The donation helped 2,780 people over three months in 2023.
The war between a rebel group and the loyalist FARDC army has been going on for nearly two years. Camp Don Bosco was set up in the fall of 2022. Don Bosco Ngangi Youth Center welcomed the displaced people and allowed them to use a plot of land that was once used for youth sports activities. Most of the 21,000 people camped on the land were displaced from Rutshuru and Nyiragongo.
A Salesian noted, “The highly nutritious food from Feed My Starving Children has been warmly welcomed by the families living in the camp. The families know that they are getting much-needed nutrition and are able to provide healthy meals for their families. Families with children testify that this food is highly nutritious and facilitates a quick recovery of malnourished children.”
HAITI Salesian students in Haiti received healthy nutrition thanks to a partnership between Salesian Missions and Rise Against Hunger. The shipment was received by the Salesian-run Vincent Foundation and then distributed to seven Salesian centers and schools in the second half of 2023. More than 3,100 youth were impacted by the donation.
The Vincent Foundation school, located southwest of Cap-Haïtien, was founded by President Stentio Joseph Vincent in 1936. It was handed over to the Salesians in 1955. The professional school offers courses in tailoring, cabinetmaking, automobile mechanics, electricity and agricultural technology. In addition to this school, the shipment was shared with Don Bosco Technique, Lakay Don Bosco, Timkatec, Lakay Foyer and Atelier, and Lakou CDR and Atelier.
Salesians serve vulnerable youth around the country. Haiti is experiencing high levels of insecurity, including looting and hostage-taking. The Cap-Haïtien area is also facing extremely high inflation and almost complete unavailability of fuel for transportation.
NAMIBIA Don Bosco Private School in Namibia received classroom furniture thanks to a donation from Furniture Reuse Solutions secured by Salesian Missions. Furniture Reuse Solutions has a commitment to sustainability and societal benefit. The company provides charities and nonprofits with gifts-in-kind donations that aid in their humanitarian missions.
The furniture is being used in the classrooms, computer lab, staff room and small school hall. All of these locations lacked furniture before this donation arrived. The donation has impacted 230 students, 16 teaching staff and indirectly more than 500 parents who are happy with the resources for their children.
The combination of desks and chairs for students is the first of its kind at Don Bosco Private School. Salesians report that the furniture has made the learning environment more relaxing for the students, who would have otherwise been disadvantaged because of the lack of desks and chairs. The new desks and chairs also create neatness in the class and with more space for movement among the rows and for class activities. Both students and teachers appreciate the new classroom set-up. The school plans to add more classrooms in order to better serve the local population.
NIGERIA The Salesian Hostel in the Don Bosco community of Onitsha, located in the Anambra State of Nigeria, has the support needed for a new roof project thanks to donor funding from Salesian Missions. While the roof is not yet completed, the funding helped pay for construction of roof beams, fabrication of the iron trusses, and connection, fixing and anchorages of the structural steel works.
Close to 800 youth, ages 11-18, are boarders of the hostel and will benefit from this project. The roof also creates a safer workplace for educators, Salesian staff and personnel at the hostel. A Salesian noted, “This new roof is ensuring a safe and comfortable environment for everyone who is staying and working at the hostel. We are grateful for donor support.”
Salesians have been working in Nigeria since 1982, providing social and educational support for poor youth and their families. Currently, Salesians have five technical and training centers in the country, two child protection centers, a health care center, a secondary school, nine youth centers and one formation center.
Salesians also operate a school of philosophy and six job service offices to help youth who are graduating from Salesian schools with access to employment. In addition, Salesians have two farm projects and a migration office, and they have completed 41 water boreholes to ensure clean water across Nigeria.
*Any goods, services or funds provided by Salesian Missions to programs located in this country were administered in compliance with applicable laws and regulations, including sanctions administered by the U.S. Department of Treasury’s Office of Foreign Asset Control.
About Salesian Missions USA Salesian Missions is headquartered in New Rochelle, NY, and is part of the Don Bosco Network—a worldwide federation of Salesian NGOs. The mission of the U.S.-based nonprofit Catholic organization is to raise funds for international programs that serve youth and families in poor communities around the globe. The Salesian missionaries are made up of priests, brothers and sisters, as well as laypeople—all dedicated to caring for poor children throughout the world in more than 130 countries and helping young people become self-sufficient by learning a trade that will help them gain employment. To date, more than 3 million youth have received services funded by Salesian Missions. These services and programs are provided to children regardless of race or religion. For more information, go to SalesianMissions.org.
We will first present how VP1 deamidation, which has been associated with a decrease in potency, is also connected to hydrophobicity
We will investigate how production time within the bioreactor and AAV location inside or outside the cell affects capsid post-translational modifications and surface charge
We will finally demonstrate the importance of reducing and controlling the level of intermediate (partially full) and empty capsids, which can impact product efficacy and have potential implications for patient safety
After the webinar, we will host a live Q&A session, providing attendees with the opportunity to ask questions directly to the presenters. We look forward to your participation.
Join experts from Oxford Biomedica, Sarah Laughlin-Toth, Senior Scientist II Analytical Development; Thomas Thiers, Scientist II Purification Sciences; and Alex Meola, Associate Director, AAV Downstream Process Development, for the live webinar on Wednesday, September 11, 2024, at 11am EDT (4pm BST/UK).
Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at http://www.oxb.com, and follow us on LinkedIn and YouTube.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Genedata’s offerings are expected to add to Danaher’s broad workflow solutions that help accelerate the speed of drug discovery, development, and manufacturing for critical new therapies. Over the past several years Genedata and Danaher have engaged in several successful collaborations.
“Genedata is a global market leader in digitalizing R&D processes to help accelerate the delivery of lifesaving and personalized medicines. Our achievements are driven by the dedication and expertise of our teams, whose efforts have been instrumental in earning the trust of our customers,” said Othmar Pfannes, Ph.D., Founder and CEO of Genedata. “As a Danaher operating company, Genedata will seek to continue to attract the brightest talent and solve our customers’ hardest problems globally.”
“Throughout our trusted relationship with Genedata, we have long admired their innovative software systems anchored in deep scientific expertise. We share a commitment to supporting biopharma companies to accelerate the development of much-needed therapies by providing innovative solutions that help researchers access high-quality insights,” said Greg Milosevich, Vice President and Group Executive of Danaher’s DH Life Sciences LLC subsidiary. “We are excited to welcome their team to Danaher and intend to continue expanding Genedata’s capabilities to address new technologies and requirements in this quickly evolving field.”
About Genedata Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help support the return-on-investment attributable to R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo. http://www.genedata.com LinkedIn | X (Twitter) | YouTube [email protected]
About Danaher Corporation Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to help solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our 65,000+ associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at http://www.danaher.com. ________________________________________
FORWARD-LOOKING STATEMENTS Statements in this release that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations and fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including Danaher’s 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2024. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, Danaher does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
“While GLP-1 treatments are currently expensive, there is an argument that they could be cost-effective over time due to their potential to reduce complications related to diabetes and cardiovascular events,” says Josh Schreiner, Chief Product Officer at HealthEZ. “Investing in obesity treatment may result in long-term savings by preventing the onset or progression of obesity-related issues like type 2 diabetes, and result in improved employee health.”
Given these factors, employers must consider both immediate financial implications and future health outcomes when deciding on health plan coverage.
In the meantime, HealthEZ says a comprehensive approach to obesity management should be anchored in a smart wellness and weight loss program. HealthEZ has developed an effective program that has demonstrated strong employee engagement which is based on coaching and having registered nurses on staff, and uses educational lunch-and-learns and webinars to enhance the approach.
“Wellness programs that provide nutritional guidance, physical activity support and behavioral counseling remain a key in addressing this issue to help employees,” says Schreiner. “By providing access to a multidisciplinary approach, employers can enhance the efficacy of GLP-1 treatments and support sustainable lifestyle changes.”
Based in Bloomington, Minnesota, HealthEZ is a national independent third-party administrator of employer-sponsored, self-funded medical plans and America’s PPO, the nation’s first preferred provider organization. On a mission to make health insurance easy to understand and more efficient from provider to patient and the employers who fund their plans, HealthEZ launched EZ Pay, the nation’s first consumer medical “tap & pay” app making bills easier to understand and simpler to pay. The company partners with employers throughout the United States to deliver better access to healthcare for their employees while ensuring value and improving outcomes. More information about HealthEZ can be found at www.healthez.com.
The American Association of Oral and Maxillofacial Surgeons (AAOMS) has developed evidence-based guidance for evaluating, diagnosing and treating patients with temporomandibular joint (TMJ) disorders and intra-articular pain and dysfunction (IPD).
ROSEMONT, Ill., Aug. 19, 2024 /PRNewswire-PRWeb/ — The American Association of Oral and Maxillofacial Surgeons (AAOMS) has developed evidence-based guidance for evaluating, diagnosing and treating patients with temporomandibular joint (TMJ) disorders and intra-articular pain and dysfunction (IPD).
The position paper “The Contemporary Management of Temporomandibular Joint Intra-articular Pain and Dysfunction (IPD)” – written by members of the AAOMS Special Committee on Temporomandibular Joint Care – outlines the four key pillars for clinicians to follow in order to optimize patient care:
Conduct a thorough history, screening and physical examination.
Obtain appropriate diagnostic imaging.
Make the correct diagnosis.
Initiate the least invasive, evidence-based nonsurgical or surgical treatment.
“Significant advances in our understanding of the pathophysiology of TMJ pain and inflammation, along with the application of established principles underlying joint disease, have enabled IPD to be better diagnosed and treated. The well-documented success of nonsurgical treatment as well as minimally invasive surgical options provides the patient and surgeon with sound treatment choices,” said lead author Gary F. Bouloux, DDS, MD, MDSc, chair of the Special Committee and professor and chief of the Division of Oral and Maxillofacial Surgery at Emory University School of Medicine in Atlanta, Ga.
The most frequently used joint in the body, the TMJ is a small hinge and gliding joint located in front of the ear that allows the lower jaw to move and function. TMJ disorders are common, and symptoms can include earaches, headaches or a limited ability to open the mouth. IPD is pain that originates from the joint itself.
According to the position paper, the management of TMJ and IPD has undergone a significant transformation over the last three decades to allow for the development of evidence-based guidance to enable both providers and patients to identify best practices. Because of these advances in patient care, the National Academies in 2019 convened representatives from the Food and Drug Administration, Medical Device Epidemiology Network, patient advocacy groups, oral and maxillofacial surgeons, and orofacial pain experts to identify specific steps to improve care for patients with TMJ pain and dysfunction. The AAOMS guidance follows recommendations published by the National Academies in 2022.
The paper explains how numerous potential causes of jaw and facial pain necessitate a thorough history, screening and physical examination and suggests questions to ask patients during the evaluation process.
Regarding diagnostic imaging, the guidance indicates the appropriate initial tool is a panoramic X-ray. Based on the history, clinical examination and differential diagnosis, more advanced imaging such as cone-beam CT, medical-grade CT and MRI should be considered, the authors suggest.
When developing a diagnosis, the guidance advises clinicians to be comprehensive to ensure that other sources of pain and dysfunction are considered. “The ability to identify and recognize psychosocial factors and comorbid medical conditions is critical to assuring that patient and surgeon expectations for the outcome of any surgical procedure are concordant and realistic,” the authors explain.
The position paper also suggests initiating the least invasive nonsurgical treatments for managing IPD, which may include rest, heat, ice, nonsteroidal anti-inflammatory drugs, muscle relaxants, physical therapy and orthotics. Arthroplasty – surgery to restore the joint – or total joint replacement are surgical options that should be reserved for patients in whom minimally invasive procedures have not been successful, the authors advise.
“It is incumbent on the oral and maxillofacial surgery community – which is uniquely positioned to offer relief to patients suffering from TMJ disease – to treat patients according to the best-available level of evidence and, where possible, continue to add new knowledge to support ongoing improvements in care,” Dr. Bouloux said.
In addition to Dr. Bouloux, AAOMS Special Committee on Temporomandibular Joint Care who authored the paper include Joli C. Chou, DMD, MD, Thomas Jefferson University; William L. Chung, DDS, MD, Indiana University School of Dentistry and Hospital Medicine; Charles A. Crago, DMD, MD, Face and Jaw Surgery Center; Vince E. DiFabio, DDS, MS, University of Maryland School of Dentistry; Louis G. Mercuri, DDS, MS, University of Illinois Chicago; Gregory M. Ness, DDS, The Ohio State University; and Daniel E. Perez, DDS, MS, University of Texas Health Science Center at San Antonio.
The full paper can be found at AAOMS.org/PositionPapers and in the June issue of the Journal of Oral and Maxillofacial Surgery, AAOMS’s official journal.
Media Contact
Jolene Kremer, American Association of Oral and Maxillofacial Surgeons, 847-678-6200, [email protected], AAOMS.org
SOURCE American Association of Oral and Maxillofacial Surgeons
Dr. Kevin F. Postol, a renowned expert in sleep apnea and TMJ treatment, has been appointed President of the American Academy of Dental Sleep Medicine (AADSM), where he will lead efforts to advance dental sleep medicine and enhance patient care nationwide.
ST. LOUIS, Aug. 19, 2024 /PRNewswire-PRWeb/ — Dr. Kevin F. Postol, a leading expert in sleep apnea and TMJ treatment, has been appointed as the President of the American Academy of Dental Sleep Medicine (AADSM). This prestigious appointment recognizes Dr. Postol’s extensive experience and dedication to advancing the field of dental sleep medicine.
With over three decades of experience in dentistry and a specialized focus on sleep apnea and TMJ treatments, Dr. Postol has been instrumental in helping countless patients achieve restful and refreshing sleep. His compassionate approach, combined with his expertise in the latest therapies and treatments, has established him as a trusted figure in the dental community.
As President of the AADSM, Dr. Postol will lead efforts to promote the importance of dental sleep medicine and advocate for advancements in the field. His role will include working with professionals across the country to enhance patient care and expand the reach of effective treatments for sleep-related disorders.
Dr. Postol’s commitment to sleep health is reflected in his involvement with key initiatives, such as the White House Sleep Equity Convening. This panel, sponsored by Project Sleep, focuses on addressing sleep disparities and promoting sleep health equity, particularly in underserved communities. Dr. Postol’s contributions highlight the critical role of sleep health in overall well-being and the need for comprehensive approaches to treatment.
At Gateway Center for Sleep Apnea & TMJ Therapy, Dr. Postol leads a dedicated team that offers a range of non-invasive treatments, including oral appliance therapy, to manage snoring and obstructive sleep apnea. His patient-centric approach ensures that each individual receives personalized care tailored to their specific needs.
For more information about Dr. Kevin F. Postol and the services offered at the Gateway Center for Sleep Apnea & TMJ Therapy, please visit www.gatewaysleepandtmj.com or contact the office at 636-394-9587.
About Gateway Center for Sleep Apnea & TMJ Therapy
Gateway Center for Sleep Apnea & TMJ Therapy, located in St. Louis, MO, is dedicated to helping patients achieve quality sleep and relief from TMJ-related pain. Led by Dr. Kevin F. Postol, the center focuses on compassionate care and effective treatments to improve overall health and well-being. The team’s expertise in dental sleep medicine makes them a leading provider of solutions for sleep apnea and TMJ disorders.
The Nevada Supreme Court has reversed the dismissal of the case Adkins, et al. vs. Union Pacific Railroad Company, et al., allowing the plaintiffs, represented by Joel Henriod and Erica Entsminger of Eglet Adams Eglet Ham Henriod, to proceed with their claims. The case, involving personal injury and wrongful death claims due to toxic chemical exposure at the Clark County Government Center, can now move forward to discovery and trial. The Court’s decision emphasized the applicability of the discovery rule and equitable tolling, allowing the plaintiffs’ claims despite the initial statute of limitations dismissal. This ruling is a significant victory for the plaintiffs and reinforces the protection of individuals harmed by corporate negligence.
LAS VEGAS, Aug. 17, 2024 /PRNewswire-PRWeb/ — In a significant victory for the plaintiffs, the Nevada Supreme Court has reversed a lower court’s dismissal of the case Adkins, et al. vs. Union Pacific Railroad Company, et al., and ruled in favor of the injured plaintiffs represented by appellate attorneys Joel Henriod and Erica Entsminger of the law firm Eglet Adams Eglet Ham Henriod.
The case that was filed by pro hac vice attorney Lindsay Dibler of Missouri and local counsel Craig Mueller, involving personal injury and wrongful death claims arising from exposure to toxic chemicals in the Clark County Government Center (CCGC) that caused numerous Clark County employees to contract terminal cancer and led to multiple employee deaths, may now proceed to discovery and trial following this critical decision. The plaintiffs brought claims against Union Pacific Railroad who previously owned the property, the manufacturers of polychlorinated biphenyls (PCBs) (all Monsanto companies), and those who were involved with the associated CalNev Pipeline. Plaintiffs seek damages for current and former CCGC employees exposed to toxic chemicals present in and around the CCGC building.
The case was initially dismissed by the Eighth Judicial District Court in Clark County on the grounds that the plaintiffs’ claims were barred by the statute of limitations. However, the Nevada Supreme Court reversed that decision on August 15, 2024, concluding that the discovery rule and the doctrine of equitable tolling may toll the two-year statute of limitations in situations where the plaintiffs were unaware of their claims because they never knew about the toxins in the soil under the building, or that their illnesses were diagnosed years after working in the building, or of the potential connection between the toxins and their illnesses. The complaint also alleges that supervisors in the building had deflected employee complaints and concerns over the years and no one ever informed workers about the contaminated ground.
The Court’s ruling emphasized that, even with diligent investigation, the plaintiffs might not have reasonably discovered the facts supporting their cause of action earlier. This decision aligns with prior precedent and reinforces the application of the discovery rule to personal injury cases in Nevada.
“This ruling affirms the courthouse will not be shut to victims simply because they receive their diagnoses and learn the cause of their illnesses more than two years after first exposure to toxic chemicals, especially when they’ve been told there is no problem,” said Joel Henriod, a partner at Eglet Adams Eglet Ham Henriod. Erica Entsminger, also representing the plaintiffs, added, “This victory is not just for our clients, but for all individuals who have been wronged by corporate negligence and have been unfairly denied justice due to technicalities like the statute of limitations.”
This decision marks a critical step forward for the plaintiffs in their fight against those responsible for the toxic exposure that has caused so much harm in the community.
Senior Partner Robert Eglet, ranked among the top five trial lawyers in America, will serve as lead trial counsel in this case. He has twice secured the largest verdicts in the country and has been honored as Nevada Trial Lawyer of the Year on two occasions, National Lawyer of the Year in 2010, and National Trial Lawyer of the Year in 2014.
The Law Office of Eglet Adams Eglet Ham Henriod is one of the most successful and well-respected catastrophic injury trial firms in the country. The firm handles injuries that involve defective products, pharmaceutical negligence, sexual assaults, vehicular negligence, insurance bad faith, wrongful death, and mass torts. Eglet Adams Eglet Ham Henriod is known for its tireless advocacy on behalf of injured clients and its success in securing record-breaking verdicts and settlements. In 2023, the firm, on behalf of the State of Nevada and local governments, settled much of the opioid litigation for $1.145 billion, achieving a larger per capita settlement amount than any other state in the country.
Women We Admire is pleased to announce The Top 25 Women Chief Compliance Officers of 2024
NEW YORK, Aug. 17, 2024 /PRNewswire-PRWeb/ — Women We Admire is pleased to announce The Top 25 Women Chief Compliance Officers of 2024. In today’s complex regulatory landscape, businesses and organizations must adhere to industry-specific laws and regulations. The chief compliance officer (CCO) plays a crucial role in ensuring this adherence, mitigating risk, and preventing legal complications through the development and management of robust compliance programs. These leaders are defined by their unwavering integrity and comprehensive understanding of regulatory requirements, making them indispensable to their organizations.
First, we honor Jodi Faustlin, Chief Compliance Officer of Healthcare Compliance Pros. With a law degree and notable contributions to the healthcare field, Faustlin is dedicated to process improvement and innovation at HCP.
Next, we celebrate the career of Tracy Strong, CCO and Chief Privacy Officer of Labcorp. With over 20 years of experience and a deep knowledge of healthcare law, Strong has expertise in commercial litigation, legal research, and privacy law.
Lastly, we acknowledge financial executive Kathryn Vengerovskiy, CCO and Vice President of Legal at True Green Capital Management LLC. With a solid background in corporate and transportation law, Vengerovskiy specializes in legal structuring and documentation for tax equity, debt, and sale-leaseback financings.
Please join us in celebrating the accomplishments of The Top 25 Women Chief Compliance Officers of 2024.
Tamsin Fast (Aramark), Jillian Marcus (Envision Healthcare), Rowena Spigarelli (RWJBarnabas Health), Leah Voigt (Corewell Health), Tracy Strong (Labcorp), Jacqueline Thomas (Toyota North America), Kerry Brady (Community Options, Inc.), Kathryn Vengerovskiy (True Green Capital Management LLC), Ladonna Resch (Bell Bank), Carolina Ceballos (Paxos), Pierrette Bradshaw (MidCap Financial), Jodi Faustlin (Healthcare Compliance Pros), and many others.
Women We Admire provides news and information on today’s women leaders in business, entertainment, sports, motherhood, medicine, law, and many other fields. We cover a broad range of topics and areas of interest aimed at recognizing the achievements of exceptional women while inspiring others to aim high and continue their journey towards reaching their full potential. Women We Admire and its affiliates circulate its content to over 32,000 individuals and businesses.
